Pacific Biosciences of California Inc. buy UBS Group AG
Start price
16.02.24
/
50%
€5.53
Target price
16.02.25
€11.13
Performance (%)
-70.41%
Price
20.09.24
€1.63
Summary
This prediction is currently active. The BUY prediction by UBS_Group_AG for Pacific Biosciences of California Inc. is performing very badly with a performance of -70.41%. This prediction currently runs until 16.02.25. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacific Biosciences of California Inc. | 0.282% | 0.282% |
iShares Core DAX® | 0.347% | 2.173% |
iShares Nasdaq 100 | 0.715% | 0.138% |
iShares Nikkei 225® | 1.522% | 2.003% |
iShares S&P 500 | 0.631% | 1.633% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at UBS Group AG from $12.50 to $12.00. They now have a "buy" rating on the stock.
Ratings data for PACB provided by MarketBeat
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€7.17
17.11.23
17.11.23
€9.20
17.11.24
17.11.24
-77.20%
20.09.24
20.09.24